Refine
Year of publication
- 2014 (302) (remove)
Institute
- Fachbereich Medizintechnik und Technomathematik (65)
- Fachbereich Chemie und Biotechnologie (46)
- Fachbereich Elektrotechnik und Informationstechnik (43)
- Fachbereich Wirtschaftswissenschaften (41)
- Fachbereich Energietechnik (40)
- INB - Institut für Nano- und Biotechnologien (35)
- IfB - Institut für Bioengineering (25)
- Fachbereich Maschinenbau und Mechatronik (21)
- Fachbereich Luft- und Raumfahrttechnik (13)
- Fachbereich Bauingenieurwesen (12)
Document Type
- Article (142)
- Conference Proceeding (67)
- Part of a Book (31)
- Book (21)
- Conference: Meeting Abstract (15)
- Report (8)
- Other (6)
- Bachelor Thesis (3)
- Patent (2)
- Part of a Periodical (2)
Keywords
1. Drug metabolizing enzymes and transporters play important roles in the absorption, metabolism, tissue distribution and excretion of various compounds and their metabolites and thus can significantly affect their efficacy and safety. Furthermore, they can be involved in drug–drug interactions which can result in adverse responses, life-threatening toxicity or impaired efficacy. Significant species differences in the interaction of compounds with drug metabolizing enzymes and transporters have been described.
2. In order to overcome the limitation of animal models in accurately predicting human responses, a large variety of mouse models humanized for drug metabolizing enzymes and to a lesser extent drug transporters have been created.
3. This review summarizes the literature describing these mouse models and their key applications in studying the role of drug metabolizing enzymes and transporters in drug bioavailability, tissue distribution, clearance and drug–drug interactions as well as in human metabolite testing and risk assessment.
4. Though such humanized mouse models have certain limitations, there is great potential for their use in basic research and for testing and development of new medicines. These limitations and future potentials will be discussed.
In humans, 75% of all drugs are metabolized by the cytochrome P450-dependent monooxygenase system. Enzymes encoded by the CYP2C, CYP2D, and CYP3A gene clusters account for ∼80% of this activity. There are profound species differences in the multiplicity of cytochrome P450 enzymes, and the use of mouse models to predict pathways of drug metabolism is further complicated by overlapping substrate specificity between enzymes from different gene families. To establish the role of the hepatic and extrahepatic P450 system in drug and foreign chemical disposition, drug efficacy, and toxicity, we created a unique mouse model in which 30 cytochrome P450 genes from the Cyp2c, Cyp2d, and Cyp3a gene clusters have been deleted. Remarkably, despite a wide range of putative important endogenous functions, Cyp2c/2d/3a KO mice were viable and fertile, demonstrating that these genes have evolved primarily as detoxification enzymes. Although there was no overt phenotype, detailed examination showed Cyp2c/2d/3a KO mice had a smaller body size (15%) and larger livers (20%). Changes in hepatic morphology and a decreased blood glucose (30%) were also noted. A five-drug cocktail of cytochrome P450 isozyme probe substrates were used to evaluate changes in drug pharmacokinetics; marked changes were observed in either the pharmacokinetics or metabolites formed from Cyp2c, Cyp2d, and Cyp3a substrates, whereas the metabolism of the Cyp1a substrate caffeine was unchanged. Thus, Cyp2c/2d/3a KO mice provide a powerful model to study the in vivo role of the P450 system in drug metabolism and efficacy, as well as in chemical toxicity.
Multimodal bioimage sensor
(2014)
To visualize the biochemical distribution two-dimensionally, we invented a solid-state-type ion image sensor that indicates the chemical activity of solutions and cells. The device, which consists of a CCD array covered with a functionalized membrane to detect charge accumulation, is highly sensitive to changes in the concentration and two-dimensional distribution of ions and biomaterials.
Organic anion transporting polypeptide (Oatp) 1a/1b knockout and OATP1B1 and -1B3 humanized mouse models are promising tools for studying the roles of these transporters in drug disposition. Detailed characterization of these models will help to better understand their utility for predicting clinical outcomes. To advance this approach, we carried out a comprehensive analysis of these mouse lines by evaluating the compensatory changes in mRNA expression, quantifying the amounts of OATP1B1 and -1B3 protein by liquid chromatography–tandem mass spectrometry, and studying the active uptake in isolated hepatocytes and the pharmacokinetics of some prototypical substrates including statins. Major outcomes from these studies were 1) mostly moderate compensatory changes in only a few genes involved in drug metabolism and disposition, 2) a robust hepatic expression of OATP1B1 and -1B3 proteins in the respective humanized mouse models, and 3) functional activities of the human transporters in hepatocytes isolated from the humanized models with several substrates tested in vitro and with pravastatin in vivo. However, the expression of OATP1B1 and -1B3 in the humanized models did not significantly alter liver or plasma concentrations of rosuvastatin and pitavastatin compared with Oatp1a/1b knockout controls under the conditions used in our studies. Hence, although the humanized OATP1B1 and -1B3 mice showed in vitro and/or in vivo functional activity with some statins, further characterization of these models is required to define their potential use and limitations in the prediction of drug disposition and drug-drug interactions in humans.
The 2nd edition of the lightning risk management
standard (IEC 62305-2) considers structures, which may
endanger environment. In these cases, the loss is not limited to
the structure itself, which is valid for usual structures. In the past
(Edition 1) this danger was simply taken into account by a special
hazard factor, multiplying the existing risk for the structure with
a number. Now, in the edition 2, we add to the risk for the
structure itself a “second risk” due to the losses outside the
structure. The losses outside can be treated independently from
what occurs inside. This is a major advantage to analyze the risk
for sensitive structures, like chemical plants, nuclear plants, or
structures containing explosives, etc. In this paper, the existing
procedure given by the European version EN 62305-2 Ed.2 is
further developed and applied to a few structures.
Die Informationsbroschüre „3D-Druck – Prozessmanagement für individualisierte Massenprodukte“ richtet sich an 3D-Druckdienstleister, die additive Fertigungsverfahren (Additive Manufacturing) nutzen, sowie an IT-Dienstleister, die eine Plattform für den Datenaustausch und die Individualisierung anbieten.
Mit der additiven 3D-Drucktechnologie erfolgt die Fertigung von Produkten durch einen schichtweisen Aufbau. In dieser Broschüre werden mögliche Potenziale im Bereich der Herstellung mittels additiver Fertigungsverfahren aufgezeigt.